⌘K
Loading ticker…
Recursion Pharmaceuticals, Inc. Class A Common Stock · Healthcare · Pharmaceutical Products
As of 2026-06-26, Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) has a 3-month relative strength percentile of 60 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 45. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 8.1%, relative volume 2.04×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
60 is not yet a leadership-grade RS read, Market Stance is 47
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY diluted average shares. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
RXRX is held by 8 ETFs as of Mar 2026. Top owner: XBI at 0.69% weight, $51M notional. Top 3 carry $134M.
Top 8 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| XBIState Street SPDR S&P Biotech ETF | 0.69% | $51M |
| VTIVanguard Total Stock Market ETF | 0.00% | $48M |
| VBVanguard Small Cap ETF | 0.02% | $35M |
| IWMiShares Russell 2000 ETF | 0.05% | $34M |
| VBKVanguard Small-Cap Growth ETF | 0.05% | $20M |
| VXFVanguard Extended Market ETF | 0.02% | $18M |
| IWOiShares Russell 2000 Growth ETF | 0.09% | $11M |
| ITOTiShares Core S&P Total U.S. Stock Market ETF | 0.00% | $2M |
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | RXRX Jan avg: 3.26% median: 4.77% win: 75% σ: 5.76% n: 4 2022-04-12 → 2026-05-29 | RXRX Feb avg: 8.05% median: 0.78% win: 50% σ: 24.26% n: 4 2022-04-12 → 2026-05-29 | RXRX Mar avg: -22.50% median: -22.04% win: 0% σ: 6.28% n: 4 2022-04-12 → 2026-05-29 | RXRX Apr avg: -8.31% median: -9.88% win: 40% σ: 17.48% n: 5 2022-04-12 → 2026-05-29 | RXRX May avg: 13.40% median: 3.76% win: 60% σ: 41.30% n: 5 2022-04-12 → 2026-05-29 | RXRX Jun avg: 7.45% median: 5.82% win: 50% σ: 23.23% n: 4 2022-04-12 → 2026-05-29 (current) | RXRX Jul avg: 29.97% median: 13.46% win: 100% σ: 39.77% n: 4 2022-04-12 → 2026-05-29 | RXRX Aug avg: -11.59% median: -16.11% win: 25% σ: 26.40% n: 4 2022-04-12 → 2026-05-29 | RXRX Sep avg: -4.12% median: -4.12% win: 50% σ: 7.83% n: 4 2022-04-12 → 2026-05-29 | RXRX Oct avg: -5.70% median: -2.47% win: 25% σ: 18.43% n: 4 2022-04-12 → 2026-05-29 | RXRX Nov avg: 3.65% median: 0.48% win: 50% σ: 21.22% n: 4 2022-04-12 → 2026-05-29 | RXRX Dec avg: 2.48% median: -8.02% win: 25% σ: 28.19% n: 4 2022-04-12 → 2026-05-29 |